Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children Aged 12-17 Years in Indonesia

Next Previous
Trial Profile

A Phase III, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children Aged 12-17 Years in Indonesia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SARS CoV 2 vaccine-PT Bio Farma (Primary) ; COVID-19 vaccine adjuvanted Novavax
  • Indications COVID 2019 infections
  • Focus Pharmacodynamics
  • Sponsors PT Bio Farma

Most Recent Events

  • 03 Jun 2025 Status changed from recruiting to completed.
  • 17 Apr 2023 Planned End Date changed from 31 Dec 2022 to 31 Jan 2024.
  • 17 Apr 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top